NEW YORK, March 12 /PRNewswire-FirstCall/ -- Advance Nanotech, Inc., (OTC Bulletin Board: AVNA), today announced that the Company's majority owned subsidiary, Owlstone Nanotech, Inc., has received an initial purchase order from Genzyme Corporation one of the world's leading biotechnology companies, for its Lonestar detection system. Bret Bader, CEO of Advance Nanotech, said, "As a result of our superior FAIMS based solution, we continue to make strong progress in unlocking the future revenue potential of significant strategic applications. We see this initial contract as a launching pad to further business development in the pharmaceutical industry."
There are numerous potential opportunities to apply Lonestar's high speed sensitive and selective detection capabilities in pharmaceutical manufacturing where there is a need to analyze solvent levels in the headspace of a process line. Owlstone's Lonestar is ideal for integration into pharmaceutical process lines to optimize manufacturing throughput and reduce costs.
Genzyme approached Owlstone with specific detection requirements for solvents that are difficult to identify at low concentrations with other products and technologies. During feasibility trials, Lonestar successfully demonstrated its capability to detect the analyte while meeting operational constraints for infield use.
Dylan Jones, Senior Manager Process Analytics at Genzyme said, "Genzyme is committed to finding medical treatments for people with serious diseases. We are pleased to invest in innovative technologies where we see opportunities to explore better ways of ensuring our patients get the quality of medication they require."
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown fro
|SOURCE Advance Nanotech, Inc.|
Copyright©2009 PR Newswire.
All rights reserved